REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Professor of Genetic Medicine and Board Member of Adverum, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Wednesday, August 13, 2025 at 9:00am EDT.
Related Questions
Will any regulatory or reimbursement discussions be featured that could impact future revenue forecasts?
Could the fireside chat raise the visibility of ADVM among analysts and potentially lead to coverage upgrades?
How might the participation of the CEO and board member at this conference influence ADVM's short‑term share price?
Does the conference provide an opportunity to secure new partnerships or collaborations for Adverum's ophthalmology pipeline?
Could the sentiment score of 45 indicate market caution and affect investor perception of the announcement?
Will any material corporate updates or trial data be disclosed during the fireside chat?
Might the management commentary address competitive positioning versus rivals like Astellas, Novartis, or Roche?
What comparable events have other gene‑therapy ophthalmology companies held, and how did their stock react?
How does this conference align with Adverum's long‑term strategic milestones and product launch timelines?
Is there an expectation of increased trading volume or volatility around the conference date?